Valo Health Signs an Agreement with Novo Nordisk to Discover and Develop Novel Treatments for Cardiometabolic Diseases
Shots:
- Valo will receive an up front & near-term milestone fee of ~$60M and is eligible to receive ~$2.7B as an additional milestone for up to 11 programs along with R&D funding & royalty
- The collaboration will use Valo’s Opal Computational Platform, real-world patient data set, AI-enabled small molecule discovery & Biowire human tissue modeling platform to discover & develop novel cardiometabolic drug programs
- Novo Nordisk will license three of Valo’s preclinical cardiovascular drug programs using the Opal Computational Platform. Valo's preclinical capabilities allow the discovery and validation of novel druggable targets, the development of drug candidates against targets & the prediction of compound safety and efficacy
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Reports P-III Trial (STEP-HFpEF) Results of Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
